BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18813810)

  • 1. Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats.
    Yamamoto M; Kurita A; Asahara T; Takakura A; Katono K; Iwasaki M; Ryuge S; Wada M; Onoda S; Yanaihara T; Yokoba M; Mitsufuji H; Nishii Y; Fukui T; Masuda N
    Oncol Rep; 2008 Oct; 20(4):727-30. PubMed ID: 18813810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.
    Kurita A; Kado S; Matsumoto T; Asakawa N; Kaneda N; Kato I; Uchida K; Onoue M; Yokokura T
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):201-13. PubMed ID: 20354702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid deconjugation of SN-38 glucuronide and adsorption of released free SN-38 by intestinal microorganisms in rat.
    Takakura A; Kurita A; Asahara T; Yokoba M; Yamamoto M; Ryuge S; Igawa S; Yasuzawa Y; Sasaki J; Kobayashi H; Masuda N
    Oncol Lett; 2012 Mar; 3(3):520-524. PubMed ID: 22740943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
    Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
    Cancer Chemother Pharmacol; 1998; 42(4):280-6. PubMed ID: 9744772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats.
    Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
    Cancer Res; 1996 Aug; 56(16):3752-7. PubMed ID: 8706020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.
    Takasuna K; Hagiwara T; Watanabe K; Onose S; Yoshida S; Kumazawa E; Nagai E; Kamataki T
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):494-503. PubMed ID: 16437251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.
    Yang XX; Hu ZP; Chan SY; Duan W; Ho PC; Boelsterli UA; Ng KY; Chan E; Bian JS; Chen YZ; Huang M; Zhou SF
    Curr Drug Metab; 2006 May; 7(4):431-55. PubMed ID: 16724931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats.
    Onoue M; Kurita A; Kado S; Matsumoto T; Kaneda N; Uchida K; Kato I; Yokokura T
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):595-605. PubMed ID: 17549477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea.
    Ikegami T; Ha L; Arimori K; Latham P; Kobayashi K; Ceryak S; Matsuzaki Y; Bouscarel B
    Cancer Res; 2002 Jan; 62(1):179-87. PubMed ID: 11782376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats.
    Kurita A; Kado S; Kaneda N; Onoue M; Hashimoto S; Yokokura T
    Cancer Chemother Pharmacol; 2000; 46(3):211-20. PubMed ID: 11021738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
    Gupta E; Lestingi TM; Mick R; Ramirez J; Vokes EE; Ratain MJ
    Cancer Res; 1994 Jul; 54(14):3723-5. PubMed ID: 8033091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biliary excretion of irinotecan and its metabolites.
    Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
    J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats.
    Takasuna K; Kasai Y; Kitano Y; Mori K; Kobayashi R; Hagiwara T; Kakihata K; Hirohashi M; Nomura M; Nagai E
    Jpn J Cancer Res; 1995 Oct; 86(10):978-84. PubMed ID: 7493918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Organic Anion Transporting Polypeptide (OATP)2B1 Contributes to Gastrointestinal Toxicity of Anticancer Drug SN-38, Active Metabolite of Irinotecan Hydrochloride.
    Fujita D; Saito Y; Nakanishi T; Tamai I
    Drug Metab Dispos; 2016 Jan; 44(1):1-7. PubMed ID: 26526067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches to prevent intestinal toxicity of irinotecan-based regimens.
    Alimonti A; Gelibter A; Pavese I; Satta F; Cognetti F; Ferretti G; Rasio D; Vecchione A; Di Palma M
    Cancer Treat Rev; 2004 Oct; 30(6):555-62. PubMed ID: 15325035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of irinotecan.
    Kuhn JG
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):39-42. PubMed ID: 9726089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.
    Mick R; Gupta E; Vokes EE; Ratain MJ
    J Clin Oncol; 1996 Jul; 14(7):2012-9. PubMed ID: 8683231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adsorption of irinotecan onto oral adsorbent AST-120 (Kremezin) for preventing delayed diarrhea.
    Hidaka M; Yamasaki K; Okumura M; Ogikubo T; Iwakiri T; Setoguchi N; Nishida K; Nagai K; Ikenoue T; Arimori K
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):321-8. PubMed ID: 16770581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The contribution of intestinal UDP-glucuronosyltransferases in modulating 7-ethyl-10-hydroxy-camptothecin (SN-38)-induced gastrointestinal toxicity in rats.
    Tallman MN; Miles KK; Kessler FK; Nielsen JN; Tian X; Ritter JK; Smith PC
    J Pharmacol Exp Ther; 2007 Jan; 320(1):29-37. PubMed ID: 17003228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
    Yang XX; Hu ZP; Xu AL; Duan W; Zhu YZ; Huang M; Sheu FS; Zhang Q; Bian JS; Chan E; Li X; Wang JC; Zhou SF
    J Pharmacol Exp Ther; 2006 Oct; 319(1):82-104. PubMed ID: 16815871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.